Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 2, 2010, Pages 404-409

  De Simone, Giuseppina ^a   Supuran, Claudiu T ^b  

^a CNR   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase IX; CO2 hydration; Drug design; Sulfonamide inhibitor; X ray crystallography

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; COUMARIN DERIVATIVE; DIMER; ISOENZYME; PHENOL DERIVATIVE; PROTEOGLYCAN; SULFANILAMIDE; SULFONAMIDE; TUMOR MARKER;

BIOCHEMISTRY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ADHESION; CELL MEMBRANE; CHEMICAL STRUCTURE; CRYSTALLOGRAPHY; DISULFIDE BOND; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPOXIA; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN QUATERNARY STRUCTURE; REVIEW;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CRYSTALLOGRAPHY; HUMANS; NEOPLASMS;

ANIMALIA; MAMMALIA;

EID: 74449091486     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.07.027     Document Type: Review

References (28)

1. Supuran C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 7 (2008) 168-181
2. Pastorekova S., Zavadova Z., Kostal M., Babusikova O., and Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 187 (1992) 620-626
3. Zavada J., Zavadova Z., Pastorekova S., Ciampor F., Pastorek J., and Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer 54 (1993) 268-274
4. Pastorek J., Pastorekova S., Callebaut I., Mornon J.P., Zelnik V., Opavsky R., Zatovicova M., Liao S., Portetelle D., Stanbridge E.J., Zavada J., Burny A., and Kettmann R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 9 (1994) 2877-2888
5. Opavsky R., Pastorekova S., Zelnik V., Gibadulinova A., Stanbridge E.J., Zavada J., Kettmann R., and Pastorek J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33 (1996) 480-487
6. Pastoreková S., and Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic anhydrase: its inhibitors and activators (2004), CRC Press, Boca Raton, FL 255-281
7. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
8. Potter C.P., and Harris A.L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer 89 (2003) 2-7
9. Pouyssegur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
10. Wingo T., Tu C., Laipis P.J., and Silverman D.N. The catalytic properties of human carbonic anhydrase IX. Biochem. Biophys. Res. Commun. 288 (2001) 666-669
11. Hilvo M., Baranauskiene L., Salzano A.M., Scaloni A., Matulis D., Innocenti A., Scozzafava A., Monti S.M., Di Fiore A., De Simone G., Lindfors M., Janis J., Valjakka J., Pastorekova S., Pastorek J., Kulomaa M.S., Nordlund H.R., Supuran C.T., and Parkkila S. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J. Biol. Chem. 283 (2008) 27799-27809
12. Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., and Supuran C.T. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 13 (2003) 1005-1009
13. Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., and Supuran C.T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions. J. Enzym. Inhib. Med. Chem. 18 (2003) 403-406
14. V. Alterio, M. Hilvo, A. Di Fiore, C.T. Supuran, P. Pan, S. Parkkila, A. Scaloni, J. Pastorek, S. Pastorekova, S.M. Monti, A. Scozzafava, G. De Simone, Crystal structure of the extracellular catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc. Natl. Acad. Sci. USA (in press).
15. Hurt J.D., Tu C., Laipis P.J., and Silverman D.N. Catalytic properties of murine carbonic anhydrase IV. J. Biol. Chem. 272 (1997) 13512-13518
16. Innocenti A., Vullo D., Scozzafava A., and Supuran C.T. Carbonic anhydrase inhibitors. Interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). Bioorg. Med. Chem. Lett. 18 (2008) 1583-1587
17. Maresca A., Temperini C., Vu H., Pham N.B., Poulsen S.A., Scozzafava A., Quinn R.J., and Supuran C.T. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J. Am. Chem. Soc. 131 (2009) 3057-3062
18. Pastorekova S., Casini A., Scozzafava A., Vullo D., Pastorek J., and Supuran C.T. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 14 (2004) 869-873
19. Casey J.R., Morgan P.E., Vullo D., Scozzafava A., Mastrolorenzo A., and Supuran C.T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 47 (2004) 2337-2347
20. Winum J.-Y., Pastorekova S., Jakubickova L., Montero J.-L., Scozzafava A., Pastorek J., Vullo D., Innocenti A., and Supuran C.T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with bis-sulfamates. Bioorg. Med. Chem. Lett. 15 (2005) 579-584
21. Dubois L., Lieuwes N.G., Maresca A., Thiry A., Supuran C.T., Scozzafava A., Wouters B.G., and Lambin P. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother. Oncol. 92 (2009) 423-428
22. Cecchi A., Hulikova A., Pastorek J., Pastoreková S., Scozzafava A., Winum J.-Y., Montero J.-L., and Supuran C.T. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J. Med. Chem. 48 (2005) 4834-4841
23. Švastová E., Hulíková A., Rafajová M., Zatovicová M., Gibadulinová A., Casini A., Cecchi A., Scozzafava A., Supuran C.T., Pastorek J., and Pastoreková S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577 (2004) 439-445
24. Wilkinson B.L., Bornaghi L.F., Houston T.A., Innocenti A., Supuran C.T., and Poulsen S.-A. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J. Med. Chem. 49 (2006) 6539-6548
25. Swietach P., Wigfield S., Cobden P., Supuran C.T., Harris A.L., and Vaughan-Jones R.D. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J. Biol. Chem. 283 (2008) 20473-20483
26. Chiche J., Ilc K., Laferrière J., Trottier E., Dayan F., Mazure N.M., Brahimi-Horn M.C., and Pouysségur J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 69 (2009) 358-368
27. J.K.J. Ahlskog, C.E. Dumelin, S. Trüssel, J. Marlind, D. Neri, In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives, Bioorg. Med. Chem. Lett. 19 (2009) 4851-4856, doi:10.1016/j.bmcl.2009.06.022.
28. Dubois L., Douma K., Supuran C.T., Chiu R.K., van Zandvoort M.A.M.J., Pastoreková S., Scozzafava A., Wouters B.G., and Lambin P. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother. Oncol. 83 (2007) 367-373